Patient characteristics before ICE chemotherapy
| Patient characteristic . | No. patients . |
|---|---|
| Age (y) | |
| Median (range) | 46 (20-66) |
| Younger than 60 | 75 |
| 60 or older | 10 |
| Response to primary therapy | |
| Induction partial response (IPR) | 40 |
| Induction failure (IF) | 45 |
| Histologic diagnosis (WHO classification) | |
| Diffuse large B-cell | 71 |
| Peripheral T-cell lymphoma, unspecified | 12 |
| Anaplastic large cell: T-cell | 2 |
| Stage | |
| I | 1 |
| II | 17 |
| III | 7 |
| IV | 60 |
| Karnofsky performance status | |
| ≥80 | 45 |
| <80 | 40 |
| Extranodal sites involved | |
| ≤1 | 38 |
| >1 | 47 |
| Bone marrow involvement | |
| Yes | 20 |
| No | 65 |
| Prior chemotherapy | |
| 1 prior regimen | 74 |
| CHOP | 34 |
| CHOP-like | 9 |
| NHL-15* | 31 |
| ≥2 regimens | 11 |
| including CHOP | 10 |
| including CHOP-like chemotherapy | 1 |
| Second-line IPI | |
| 1 | 19 |
| 2 | 22 |
| 3 | 18 |
| 4 | 26 |
| Age-adjusted second-line IPI | |
| 1 | 8 |
| 2 | 22 |
| 3 | 28 |
| 4 | 27 |
| Patient characteristic . | No. patients . |
|---|---|
| Age (y) | |
| Median (range) | 46 (20-66) |
| Younger than 60 | 75 |
| 60 or older | 10 |
| Response to primary therapy | |
| Induction partial response (IPR) | 40 |
| Induction failure (IF) | 45 |
| Histologic diagnosis (WHO classification) | |
| Diffuse large B-cell | 71 |
| Peripheral T-cell lymphoma, unspecified | 12 |
| Anaplastic large cell: T-cell | 2 |
| Stage | |
| I | 1 |
| II | 17 |
| III | 7 |
| IV | 60 |
| Karnofsky performance status | |
| ≥80 | 45 |
| <80 | 40 |
| Extranodal sites involved | |
| ≤1 | 38 |
| >1 | 47 |
| Bone marrow involvement | |
| Yes | 20 |
| No | 65 |
| Prior chemotherapy | |
| 1 prior regimen | 74 |
| CHOP | 34 |
| CHOP-like | 9 |
| NHL-15* | 31 |
| ≥2 regimens | 11 |
| including CHOP | 10 |
| including CHOP-like chemotherapy | 1 |
| Second-line IPI | |
| 1 | 19 |
| 2 | 22 |
| 3 | 18 |
| 4 | 26 |
| Age-adjusted second-line IPI | |
| 1 | 8 |
| 2 | 22 |
| 3 | 28 |
| 4 | 27 |
The details of the NHL-15 regimen have been described elsewhere.27